微芯生物
(688321)
| 流通市值：141.22亿 | | | 总市值：141.22亿 |
| 流通股本：4.08亿 | | | 总股本：4.08亿 |
| 报告期 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 490,156,626.11 | 369,285,450.12 | 375,224,219.84 | 347,472,935.32 |
| 交易性金融资产 | 77,007,272.22 | 133,158,207.65 | 94,134,341.67 | 134,282,130.33 |
| 应收票据及应收账款 | 207,011,418.47 | 139,251,135.31 | 162,437,516.37 | 146,238,028.01 |
| 其中：应收票据 | - | - | 2,440,664.1 | - |
| 应收账款 | 207,011,418.47 | 139,251,135.31 | 159,996,852.27 | 146,238,028.01 |
| 预付款项 | 6,462,135.5 | 11,653,496.31 | 5,913,018.69 | 11,110,228.1 |
| 其他应收款合计 | 7,916,635.41 | 8,470,203.04 | 15,418,571.95 | 29,769,616.16 |
| 存货 | 54,616,769.12 | 50,753,968.26 | 40,843,656.94 | 49,417,728.34 |
| 合同资产 | 1,008,277.16 | 1,198,161.12 | 536,507.54 | 2,522,615.76 |
| 其他流动资产 | 402,220,256.83 | 421,057,000.91 | 388,963,718.64 | 377,796,393.57 |
| 流动资产合计 | 1,246,399,390.82 | 1,134,827,622.72 | 1,083,471,551.64 | 1,098,609,675.59 |
| 非流动资产: | | | | |
| 长期股权投资 | 238,836,734.35 | 240,619,976.13 | 245,633,109.36 | 252,518,862.66 |
| 投资性房地产 | 117,916,983.54 | 118,796,234.09 | 117,479,085.13 | 120,299,730.56 |
| 固定资产 | 780,977,662.48 | 778,407,482.79 | 761,748,354.36 | 742,420,044.15 |
| 在建工程 | 371,537,304.91 | 372,546,524.6 | 384,864,121.69 | 407,309,749.1 |
| 使用权资产 | 9,284,375.8 | 10,181,493.84 | 10,929,572.43 | 11,730,390.85 |
| 无形资产 | 432,985,626 | 440,507,935.96 | 448,287,024.71 | 436,573,194.43 |
| 开发支出 | 193,008,289.66 | 172,362,595.26 | 152,216,111.48 | 227,061,689.42 |
| 长期待摊费用 | 16,222,946.88 | 15,433,110.41 | 16,080,870.24 | 8,393,088.57 |
| 递延所得税资产 | 1,526,958.65 | 1,466,300.91 | 1,532,434.82 | 3,232,144.37 |
| 其他非流动资产 | 26,106,920.03 | 26,553,851.66 | 28,656,822.32 | 29,992,597.72 |
| 非流动资产合计 | 2,188,403,802.3 | 2,176,875,505.65 | 2,167,427,506.54 | 2,239,531,491.83 |
| 资产总计 | 3,434,803,193.12 | 3,311,703,128.37 | 3,250,899,058.18 | 3,338,141,167.42 |
| 流动负债: | | | | |
| 短期借款 | 135,041,361.11 | 135,035,416.67 | 100,221,086.67 | 71,161,547.64 |
| 应付票据及应付账款 | 5,635,887.98 | 1,372,758.86 | 2,187,454.3 | 3,662,799.21 |
| 应付账款 | 5,635,887.98 | 1,372,758.86 | 2,187,454.3 | 3,662,799.21 |
| 预收款项 | 2,574,209.95 | 2,600,542.73 | 1,034,119.73 | 2,180,833.33 |
| 合同负债 | 483,789.36 | 2,575,906.84 | 169,910.66 | 413,981.21 |
| 应付职工薪酬 | 29,006,213.31 | 29,425,157.6 | 48,575,127.04 | 39,421,260.55 |
| 应交税费 | 11,271,706.77 | 9,356,741.5 | 10,929,716.44 | 11,259,268.81 |
| 其他应付款合计 | 169,425,043.95 | 171,030,853.76 | 149,372,575.49 | 142,697,612.08 |
| 一年内到期的非流动负债 | 297,067,516.72 | 130,045,902.57 | 138,821,504.33 | 109,559,457.46 |
| 流动负债合计 | 650,505,729.15 | 481,443,280.53 | 451,311,494.66 | 380,356,760.29 |
| 非流动负债: | | | | |
| 长期借款 | 565,477,783.28 | 688,939,319.95 | 646,510,856.62 | 672,732,393.29 |
| 应付债券 | 458,505,892.44 | 450,158,055.21 | 441,901,952.46 | 434,907,193.64 |
| 租赁负债 | 5,990,250.8 | 6,924,233.78 | 7,757,101.96 | 8,227,297.08 |
| 预计负债 | 606.88 | 1,596.96 | 2,560.95 | 3,164.4 |
| 递延收益 | 102,417,613.4 | 82,950,436.98 | 83,353,127.26 | 82,725,886.85 |
| 递延所得税负债 | 37,151,559.54 | 39,423,807.2 | 38,963,215.5 | 29,251,251.95 |
| 其他非流动负债 | - | - | - | 86,626,256.54 |
| 非流动负债合计 | 1,169,543,706.34 | 1,268,397,450.08 | 1,218,488,814.75 | 1,314,473,443.75 |
| 负债合计 | 1,820,049,435.49 | 1,749,840,730.61 | 1,669,800,309.41 | 1,694,830,204.04 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 407,796,477 | 407,796,477 | 407,796,477 | 407,795,845 |
| 其他权益工具 | 123,766,533.48 | 123,766,533.48 | 123,766,533.48 | 123,770,501.8 |
| 资本公积 | 1,017,470,006.96 | 1,013,197,876.53 | 1,013,197,876.53 | 1,013,179,530.75 |
| 其他综合收益 | 7,866,580.61 | 7,994,252.71 | 8,075,931.01 | 6,817,494.58 |
| 盈余公积 | 25,250,701.46 | 25,250,701.46 | 25,250,701.46 | 25,250,701.46 |
| 未分配利润 | 32,603,458.12 | -16,143,443.42 | 3,011,229.29 | 66,496,889.79 |
| 归属于母公司股东权益合计 | 1,614,753,757.63 | 1,561,862,397.76 | 1,581,098,748.77 | 1,643,310,963.38 |
| 股东权益合计 | 1,614,753,757.63 | 1,561,862,397.76 | 1,581,098,748.77 | 1,643,310,963.38 |
| 负债和股东权益合计 | 3,434,803,193.12 | 3,311,703,128.37 | 3,250,899,058.18 | 3,338,141,167.42 |
| 公告日期 | 2025-08-26 | 2025-04-26 | 2025-04-26 | 2024-10-31 |
| 审计意见(境内) | | | 标准无保留意见 | |